Panacea Biotec Ltd.
Snapshot View

356.40 +9.60 ▲2.8%

05 August 2021, 04:00:00 P.M.
Volume: 107,279

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.panacea-biotec.com
Financial Indicators
Market Cap 2,182.98 Cr.
Earnings per share (EPS) -27.90 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-06
Industry PE 32.75 Trailing Twelve Months Ending 2021-06
Book Value / Share -6.02 Trailing Twelve Months Ending 2021-06
Price to Book Value -59.25 Calculated using Price: 356.40
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 6.13 Cr. 61,250,746 Shares
FaceValue 1
Company Profile

The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.

Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2006), as well as among the top 50 pharmaceutical companies (as per ORG IMS July 2006) of India.

The company has been granted patents across countries like USA, U.K., France, Germany, Italy, Sweden, Denmark, Spain, Finland, Switzerland, The Netherlands, New Zealand, Mexico, Brazil, Nigeria, Zimbabwe, Australia, South Africa, Japan, Russia, Canada, Ukraine, Korea and China are among others.

Collaboration/ Strategic alliances The company has collaborated with Cambridge Biostability, U.K to develop thermo stable vaccines.

It has collaborated with National Institute of Immunology, India for Japanese Encephalitis candidate vaccine.

PBL has entered in strategic alliance with Biotech Consortium India to develop, manufacture and market of Anthrax vaccine.

The company has entered into an in-licensing arrangement with National Institute of Health, USA for use of a peptide based product for generation of hair follicles and hair growth.

The company has collaborated with Netherlands Vaccine Institute for inactivated polio vaccine.

It has collaborated with NRDC- India for Foot & Mouth Disease vaccine for veterinary use and Bio Farma-Indonesia for Measles vaccine.

The exclusive products based on patented Drug Delivery System include Panimun Bioral (Cyclosporine), Willgo, ThankGod (for comprehensive management of haemorrohoids), Xeed (anti-tubercular FDC with innovative Drug Delivery for optimum bioavailability of Rifampicin), Nimulid Safeinject, Nimulid MD, Nimulid Transgel. 

Commencing fiscal 2008, the company plans for international marketing of novel NDDS based pharmaceutical formulation products to the international markets, like USA, U.K., Germany, France, Latin American countries and Italy through marketing collaborations and are on the look out for partners for distribution & marketing.

Business areas Research and Development (R&D) – Under this the company primarily focuses on New Chemical Entities (NCE), New Biological Entities (NBE) and Novel Drug Delivery System (NDDS). The company has a team of 200 scientists working on different aspect of research across its four R&D centers.

Vaccines- Under this the company has product portfolio of oral polio vaccines and Hepatitis-B vaccines. It is obtaining pre-qualifications for others vaccines. The company markets its vaccines through Chiron Panacea Vaccines, this is a 50:50 joint venture with Novartis Vaccines, U.K

Formulations- It has created flagship brands like Willgo for pain management, Glizid & Glizid-M for diabetes; Panimun Bioral and Mycept for kidney transplant.

Panacea Biotec in 2009 signed an agreement with Popular Pharma for technology transfer, marketing and distribution of vaccines. Popular Pharma is engaged in manufacturing life saving drugs and has presence in various countries.

In 2010 Panacea Biotech's Baddi unit gets US FDA approval
In 2011 PanaceBiotec - Panacea Biotec Launches - PacliALL
In 2012 Panacea Biotech launches Inactivated Polio Virus vaccine in Nigeria
PanaceBiotec - Panacea Biotec inaugurates state of the art Oncology Production Unit
PanaceBiotec - Panacea Biotec Entered into Strategic Alliance with Osmotica Pharmaceutical
Panacea Biotec wins order worth Rs 187 cr from Govt to supply polio vaccines.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.77%
1 Week
+8.51%
1 Month
-10.31%
3 Month
+11.31%
6 Month
+68.75%
1 Year
+65.19%
2 Year
+199.62%
5 Year
+166.57%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -36.53 -71.43 -76.49 -253.03 -34.38 -22.94 11.39 -75.26
Return on Capital Employed (%) -10.89 -11.89 3.37 0.45 9.93 2.76 2.63 13.44 -0.38
Return on Assets (%) -10.44 -11.36 -5.47 -4.87 -1.01 -2.97 -4.53 2.55 -14.19

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 875 626 513 471 449 356 309 350 199
Non Curr. Liab. 720 865 767 918 1,100 719 591 70 737
Curr. Liab. 517 510 827 706 475 689 696 938 455
Minority Int. 7 7 5 3 1 11 -3 -3 -3
Equity & Liab. 2,119 2,008 2,112 2,099 2,025 1,774 1,592 1,356 1,388
Non Curr. Assets 1,617 1,574 1,739 1,573 1,475 1,071 1,028 848 705
Curr. Assets 501 434 373 526 549 703 565 508 683
Misc. Exp. not W/O
Total Assets 2,119 2,008 2,112 2,099 2,025 1,774 1,592 1,356 1,388

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 710 608 510 687 653 544 593 457 544
Other Income 9 5 15 28 20 47 8 5 30
Total Income 719 614 525 716 673 591 601 462 574
Total Expenditure -796 -695 -592 -643 -541 -497 -508 -590 -519
PBIDT -77 -81 -67 72 132 94 93 -128 56
Interest -101 -104 -150 -105 -127 -101 -101 -105 -174
Depreciation -77 -86 -71 -67 -73 -68 -59 -55 -44
Taxation 54 19 -2 -3 -2 11 -10 -9 -17
Exceptional Items 17 177 50 8 334 -15
PAT -201 -234 -113 -102 -21 -56 -76 38 -195

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 228 -24 54 37 91 131 118 105 -30
Cash Fr. Inv. -124 -61 -38 -37 16 -26 55 -5 -35
Cash Fr. Finan. -134 105 -30 -1 -117 -107 -164 -101 91
Net Change -29 20 -14 -1 -10 -2 9 -2 26
Cash & Cash Eqvt 15 35 21 20 10 7 16 14 40

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 73.59 73.59 73.59 73.59 73.59 73.59 73.59 73.59 73.59
Public 26.41 26.41 26.41 26.41 26.41 26.41 26.41 26.41 26.41
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 69.36 69.36 69.36 69.36 69.36 69.36 69.36 94.27 94.27

Announcements View Details

Thu, 05 Aug 2021
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (SEBI LODR Regulations) we are pleased to inform you that the Company has on August 3 2021 entered into a Licensing and Manufacturing Agreement with Human Vaccine Limited Liability Company a subsidiary of Russian Direct Investment Fund Russia GENERIUM Joint Stock Company and Dr. Reddys Laboratories Limited.

The detailed disclosure as required under Regulation 30 of SEBI LODR Regulations in respect of the above mentioned matter is annexed herewith.
Mon, 02 Aug 2021
Announcement under Regulation 30 (LODR)-Investor Presentation
In continuation to our letter dated July 28 2021 and in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith the revised Investor Presentation uploaded on the website of the Company at the link: https://www.panaceabiotec.com/comorate-presentation.
The Company will now use this presentation for meetings with analysts / institutional investors.

This is for your kind information and record please.
Wed, 28 Jul 2021
Announcement under Regulation 30 (LODR)-Investor Presentation
In compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith the Investor Presentation uploaded on the website of the Company at the link: https://www.panaceabiotec.com/corporate-presentation.

The Company will use this presentation for meetings with analysts / institutional investors.

This is for your kind information and record please.

Technical Scans View Details

Thu, 05 Aug 2021
Higher Trade Quantity Higher Trade Quantity
Closing Above Previous High Closing Above Previous High
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index
S Close Above Last Week High
CCI Trending Up CCI Trending Up

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,551.74 785.85 +0.0%
Divi's Laboratories Ltd. 130,702.13 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,575.04 4,783.30 +0.2%
Cipla Ltd. 76,243.85 945.20 +0.6%
Cadila Healthcare Ltd. 59,868.47 584.80 -0.5%
Piramal Enterprises Ltd. 59,065.41 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. 58,599.44 4,075.50 +0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.41 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 65.87 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.80 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.70 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.06 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 44.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 389.73 4,075.50 +0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.06 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.45 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.17 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.61 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.73 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.75 4,075.50 +0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 32.07 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%